| Shah, Jay P |
| Completed | 3 | 254 | US | Ebselen, SPI-1005, Placebo | Sound Pharmaceuticals, Incorporated | Meniere Disease, Ménière | 09/23 | 07/24 | | |
| Recruiting | 3 | 860 | Europe, Canada, Japan, US | Recombinant Activated Factor VII (rFVIIa), NovoSeven, NiaStase, Placebo | Joseph Broderick, MD, Novo Nordisk A/S, National Institute of Neurological Disorders and Stroke (NINDS) | Intracerebral Hemorrhage | 01/28 | 01/28 | | |
| Active, not recruiting | N/A | 900 | US | aerSleep II | Sommetrics, Inc. | Sleep Apnea, Obstructive, Apnea, Sleep | 12/25 | 12/25 | | |
NCT03193970: Measuring Surgical Recovery After Radical Cystectomy |
|
|
| Recruiting | N/A | 2000 | US | Post-Operative Recovery Registry | M.D. Anderson Cancer Center | Bladder Cancer | 12/34 | 12/34 | | |
| Korman, Neil J |
NCT05270733: Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics |
|
|
| Recruiting | 4 | 56 | US | Ustekinumab, Guselkumab, Risankizumab | University Hospitals Cleveland Medical Center, LEO Foundation, Case Western Reserve University | Psoriasis | 12/24 | 12/24 | | |
TOGETHER-PsO, NCT06588283: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight |
|
|
| Recruiting | 3 | 250 | US | Ixekizumab, LY2439821, Tirzepatide, LY3298176 | Eli Lilly and Company | Psoriasis, Obesity | 12/25 | 05/26 | | |
BRAVE-AA-PEDS, NCT05723198: A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata |
|
|
| Recruiting | 3 | 595 | Europe, Canada, Japan, US, RoW | Baricitinib, LY3009104, Placebo | Eli Lilly and Company | Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical | 09/24 | 08/29 | | |
| Recruiting | 2/3 | 474 | Europe, Canada, Japan, US, RoW | Litifilimab, BIIB059, Placebo | Biogen, Biogen Idec Research Limited | Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus | 10/26 | 12/27 | | |
NCT04877756: Study to Evaluate Efficacy of OLX10010 in Reducing Recurrence of Hypertrophic Scarring After Scar Revision Surgery |
|
|
| Completed | 2 | 22 | US | OLX10010, a cell penetrating asymmetric small interference RNA (cp-asiRNA), targeting a gene involved in formation of fibrosis | Olix Pharmaceuticals, Inc., Alira Health | Hypertrophic Scar | 01/23 | 07/23 | | |
NCT06436183: A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 60 | Canada, US | Camoteskimab, APL-9109, AVTX-007, CERC-007, AEVI-007, MEDI2338, Placebo | Apollo Therapeutics Ltd | Atopic Dermatitis, Atopic, Dermatitis, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic | 02/25 | 06/25 | | |
NCT06046729: A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa |
|
|
| Recruiting | 2 | 350 | Europe, Canada, US, RoW | Eltrekibart, LY3041658, Placebo | Eli Lilly and Company | Hidradenitis Suppurativa | 08/25 | 07/26 | | |
NCT04410237: Triamcinolone Acetonide Injections in Mild-to-moderate Chronic Plaque Psoriasis With a Novel Needle-free Drug-delivery System |
|
|
| Completed | 1 | 13 | US | Med-Jet, Traditional Syringe | University Hospitals Cleveland Medical Center | Psoriasis | 05/23 | 05/23 | | |
NCT06399432: Mediterranean Diet vs no Dietary Intervention for Improving Signs and Symptoms of Psoriasis in Patients Treated With Anti-IL-17 or Anti-IL-23 Inhibitors |
|
|
| Recruiting | N/A | 36 | US | Mediterranean Diet | Neil Korman | Psoriasis | 07/26 | 07/26 | | |
| Ross, Kristie |
NCT05757102: A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma |
|
|
| Recruiting | 3 | 292 | US, RoW | FF/UMEC/VI, ELLIPTA, FF/VI | GlaxoSmithKline | Asthma | 01/27 | 01/27 | | |
| Active, not recruiting | 3 | 1667 | Europe, Canada, Japan, US, RoW | GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS) | GlaxoSmithKline, Iqvia Pty Ltd | Asthma | 10/25 | 10/25 | | |
|
NCT04129931: PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study |
|
|
| Active, not recruiting | 2 | 395 | US | MCT, Breathe Better Diet (BBD), Clazakizumab, Anti-interleukin 6 monoclonal antibody, Anti-IL-6 mAb, BMS-945429, ALD518, Broncho-Vaxom, OM-85 BV VEGETAL, Imatinib Mesylate, Gleevec, Zoleta, Glivec, Ziatir, Cavosonstat, N91115, Placebo | University of North Carolina, Chapel Hill, National Heart, Lung, and Blood Institute (NHLBI) | Asthma | 12/24 | 12/24 | | |
NCT03617718: Project 2 Airway Potential Hydrogen (pH) in Asthma |
|
|
| Recruiting | 1/2 | 74 | US | Glycine Buffer | Case Western Reserve University, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), University Hospitals Cleveland Medical Center | Cystic Fibrosis, Asthma, Severe Persistent Asthma, Healthy | 06/27 | 06/27 | | |
NCT03926741: GSNOR Phenotyping/GSNO Challenge in Severe Asthma |
|
|
| Completed | 1 | 49 | US | GSNO | James Reynolds, University Hospitals Cleveland Medical Center, Case Western Reserve University, National Heart, Lung, and Blood Institute (NHLBI) | Asthma, Healthy Volunteers | 02/24 | 02/24 | | |
| Jeffords, Kelly |
| Recruiting | 3 | 80 | US | Hypericin, HyBryte, SGX301, Placebo | Soligenix | CTCL/ Mycosis Fungoides, CTCL, Mycosis Fungoides, Cutaneous T Cell Lymphoma | 07/26 | 10/26 | | |
| Rogers, Heather |
| Recruiting | 4 | 130 | Europe | Fluoride mouthwash (0.05%; 225ppm)., Fluorigard, Tooth Mousse Plus, Recaldent™ CPP-ACP [casein phosphopeptide (CPP)-amorphous calcium phosphate (ACP)] and Sodium Fluoride 0.2% w/w (900 ppm). | Liverpool University Hospitals NHS Foundation Trust | Orthodontic Appliance Complication, Tooth Demineralization | 09/25 | 09/25 | | |
| Active, not recruiting | N/A | 21 | US | VIA Disc Nucleus Pulposus Allograft | VIVEX Biologics, Inc. | Degenerative Disc Disease, Low Back Pain, Disc Degeneration | 08/24 | 12/24 | | |
CSM-BSI, NCT06271031: Process Mapping and Data Collection to Inform a Computer Simulation Model of Hospitalised Patients With Bloodstream Infection, Sepsis and Systemic Infection |
|
|
| Recruiting | N/A | 100 | Europe | | Liverpool University Hospitals NHS Foundation Trust | Sepsis, Bloodstream Infection, Bacteraemia | 12/25 | 03/26 | | |
